Articles by Jason M. Broderick
The use of actinium-225 PSMA radioligand therapy led to PSA level decreases of at least 50 percent in 57 percent of patients and a median progression-free survival rate of 7.9 months in patients with metastatic castration-resistant prostate cancer (mCRPC), according to newly published research.
Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
